Phaseline

Companies › Biocon Biologics UK

Biocon Biologics UK: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Bmab1700
PD-1 inhibitor (nivolumab biosimilar)
PDCD1Phase 1MelanomaAug 2027
Bmab1800
PD-1 inhibitor
PDCD1Phase 1Adult Patients With Stage IIB, IIC, and Stage III Melanoma Following Complete Resection (Adjuvant Settings)Dec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07476326Bmab1700Phase 1MelanomaOncologyAug 2027
NCT07581509Bmab1800Phase 1Adult Patients With Stage IIB, IIC, and Stage III Melanoma Following Complete Resection (Adjuvant Settings)OncologyDec 2027

Targets

PDCD1 (2)

Companies with the same targets

Akeso Sichuan Baili Pharmaceutical Innovent Biologics (Suzhou) Shanghai Henlius Biotech AstraZeneca Shenyang Sunshine Pharmaceutical Regeneron Pharmaceuticals Ono Pharmaceutical Mabwell (Shanghai) Bioscience Johnson & Johnson (Janssen)

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.